An Open-Label, Long-term Study to Assess the Immunogenicity of LINZESS® (Linaclotide) Administered Orally to Adult Participants With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation

计划入组 828 人 · 首次发布于 2015 年 10 月 29 日

Evaluation of Clinical Equivalence Between Two Linaclotide Products in the Treatment of Chronic Idiopathic Constipation

计划入组 750 人 · 首次发布于 2021 年 3 月 18 日

Efficacy of Linaclotide to Senna for CIC

计划入组 9 人 · 首次发布于 2014 年 9 月 12 日

Linaclotide(Constella, Linzess)

C₅₉H₇₉N₁₅O₂₁S₆ · Rx

Phellinus linteus mycelium

cytotoxic T-lymphocyte lines

Lineus Medical

United States

FDA Approves LINZESS for Functional Constipation in Children as Young as 2 Years Old

Linaclotide Shows Promise for Functional Constipation in Children with Neurodevelopmental Disorders

Ironwood Reports 97% LINZESS Sales Surge, Advances Apraglutide Toward STARS-2 Trial Initiation